Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Baird analyst Joel Beatty downgraded Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) from Outperform to Neutral and cut the price target from $40 to $16. Ultragenyx Pharmaceutical closed at $26.53 on Wednesday. See how other analysts view this stock . Rothschild & Co analyst Simon Baker downgraded Moderna Inc (NASDAQ: MRNA ) from Neutral to Sell and raised the price target from $40 to $81. Moderna shares closed at $150.81 on Wednesday. See how other analysts view this stock . B of A Securities analyst George Staphos downgraded Sonoco Products Co (NYSE: SON ) from Buy to Neutral and slashed the price target from $69 to $60. Sonoco closed at $54.74 on Wednesday. See how other analysts view this stock . Evercore ISI Group analyst Liisa Bayko downgraded Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) from Outperform to In-Line and lowered the price target from $34 to $16. Ultragenyx Pharmaceutical shares closed at $26.53 on Wednesday. See how other analysts view this stock .Considering buying SON stock? Here’s what analysts think:
Photo via Shutterstock
Trending Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Markets Trading Ideas Pre-Market Outlook News Analyst Ratings Downgrades Price Target Top Downgrades